Hewlett Packard Enterprise Co vs Viatris Inc — how do they compare? Hewlett Packard Enterprise Co trades at $71.77 (market cap $94.25B), while Viatris Inc trades at $17.58 (market cap $20.03B). The key difference: Hewlett Packard Enterprise Co is far larger — about 4.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Hewlett Packard Enterprise Co for 33 Days and Viatris Inc for 57 Days on average.
| HPE | VTRS | |
|---|---|---|
Market Cap | $94.25B | $20.03B |
Volume | 16,060,854 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $72.12 | $18.27 |
52-Week Low | $20.01 | $9.74 |
Typical Hold Time | 33 Days | 57 Days |
Enterprise Value | $108.28B | $32.15B |
Dividend Yield | 0.8% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
HPE trades at $71.75, near its all-time high, with strong momentum driven by AI infrastructure demand. The stock has gained over 160% year-over-year and recently received a bullish upgrade from Daiwa. Recent earnings beats and a $1.2 billion AI server order from Vultr highlight operational strength. Technical indicators show bullish moving averages but overbought RSI levels, while fundamentals reveal robust revenue growth projections to $41.9 billion in 2026.
Outlook remains positive with AI-driven growth catalysts, though valuation multiples appear elevated. Key risks include execution on Juniper integration and competitive pressures. Analyst consensus leans neutral with a $70.35 price target, suggesting limited near-term upside from current levels despite strong business momentum.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →